Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
Pharmaceuticals, ISSN: 1424-8247, Vol: 16, Issue: 3
2023
- 12Citations
- 42Usage
- 35Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations12
- Citation Indexes12
- 12
- Usage42
- Downloads34
- Abstract Views8
- Captures35
- Readers35
- 35
- Mentions1
- Blog Mentions1
- Blog1
Most Recent Blog
Pharmaceuticals, Vol. 16, Pages 415: Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
Pharmaceuticals, Vol. 16, Pages 415: Past, Present, and a Glance into the Future of Multiple Myeloma Treatment Pharmaceuticals doi: 10.3390/ph16030415 Authors: Weam Othman Elbezanti Kishore
Review Description
Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The recent treatment strategies have significantly improved progression-free survival for MM patients in the last decade; however, a relapse for most MM patients is inevitable. In this review we discuss current treatment, important pathways for proliferation, survival, immune suppression, and resistance that could be targeted for future treatments.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85152443594&origin=inward; http://dx.doi.org/10.3390/ph16030415; http://www.ncbi.nlm.nih.gov/pubmed/36986514; https://www.mdpi.com/1424-8247/16/3/415; https://rdw.rowan.edu/csm_facpub/325; https://rdw.rowan.edu/cgi/viewcontent.cgi?article=1325&context=csm_facpub; https://dx.doi.org/10.3390/ph16030415
MDPI AG
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know